Nektar Therapeutics Contract Liability (Deferred Revenue)
Nektar Therapeutics (NKTR) had Contract Liability (Deferred Revenue) of $91.00 thousand as of 2020-12-31, per its 10-K filed 2021-02-26.
Discontinued › Balance Sheet › Liabilities › Liabilities, Current › Deferred Revenue, Current
us-gaap:ContractWithCustomerLiabilityCurrent · last filed 2021-02-26
- 2020-12-31: Contract with Customer, Liability, Current $91.00K.
- 2020-09-30: Contract with Customer, Liability, Current $507.00K.
- 2020-06-30: Contract with Customer, Liability, Current $1.76M.
- 2020-03-31: Contract with Customer, Liability, Current $3.01M.
| Period end | Contract with Customer, Liability, Current |
|---|---|
| 2020-12-31 | $91.00K 10-K · filed 2021-02-26 |
| 2020-09-30 | $507.00K 10-Q · filed 2020-11-06 |
| 2020-06-30 | $1.76M 10-Q · filed 2020-08-07 |
| 2020-03-31 | $3.01M 10-Q · filed 2020-05-08 |
| 2019-12-31 | $5.52M 10-K · filed 2021-02-26 |
| 2019-09-30 | $8.39M 10-Q · filed 2019-11-07 |
| 2019-06-30 | $9.89M 10-Q · filed 2019-08-09 |
| 2019-03-31 | $11.09M 10-Q · filed 2019-05-09 |
| 2018-12-31 | $13.89M 10-K · filed 2020-02-28 |
| 2018-09-30 | $15.68M 10-Q · filed 2018-11-08 |
| 2018-06-30 | $17.99M 10-Q · filed 2018-08-09 |
| 2017-12-31 | $18.95M 10-K · filed 2019-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |